Given that small molecule therapeutics targeting MAP2K4 have been shown to inhibit cell invasion and metastasis of human PCa cells in preclinical studies, and that when tested in prospective human trials, those same therapeutics decrease MMP-2 expression in human prostate tissue, our current validation of MAP2K4 function in vivo provides essential information [11], [13]. The gene discussed is MAP2K4; the disease is posterior cortical atrophy.